Alan Raffauf, M.A. Appointed Widex Vice President of Marketing

Reaffirming its commitment to serve as the ally of the independent audiologist, Widex Inc. today announced the appointment of industry veteran Alan Raffauf, M.A. to the position of Vice President of Marketing, reporting directly to Sheena Oliver, Chief Marketing Officer, U.S.

“Alan is both an experienced B2B and B2C marketer and a professional audiologist,” Oliver said today. “As such, he brings to Widex a strong understanding of and appreciation for what today’s independent audiologists need to grow and expand their practices. Informed by his professional experience and educational background, Alan will lead the development of all Widex marketing programs, working closely with an already-stellar team of branding, creative, digital, and communications professionals.”

Alan Raffauf comes to Widex from Oticon Medical, where since 2009 he served as Vice President of Marketing with responsibility for the go-to-market readiness and lifecycle management of bone-anchored hearing products and cochlear implants for the United States and Canada. As such, he led all B2B and B2C marketing, the online patient community and advocate program, the insurance support services program, all daily operations, as well as the enterprise resource planning system.

Commenting on his appointment, Raffauf emphasized that he was joining a winning team that was growing the business. “Widex has many of the strategic pieces in place to grow at a rate that outpaces the industry,” he said today. “I am excited to join a team that is so totally committed to the independent channel. I view marketing from the perspective of the hearing care professional. I see the world through their eyes. I know what their needs are, and I am committed to developing the programs that exceed these needs.”

Prior to this position, from 2003 to 2009, he served as an Oticon Product Manager in the United States and Denmark. Finally, as a Government Services Coordinator and Staff Audiologist, he managed the VA/DDC hearing aid contract, as well as marketing and training responsibilities.

Alan Raffauf holds a Master’s Degree, Audiology/Audiologist from The College of New Jersey and a Bachelor of Arts degree in Communication Sciences and Disorders from the University of Connecticut.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.